144 filed Jun 17, 2026 at 17:25 ET
Three Form 144 filings from Kymera Therapeutics on June 17, 2026, signal intent to sell by director Bruce Booth (11,741 shares, ~$1.03M) and two Atlas Venture entities (Atlas Venture Fund X: 92,169 shares, ~$8.06M; Atlas Venture Opportunity Fund I: 12,902 shares, ~$1.13M). Combined proposed sales total ~116,812 shares worth ~$10.2M, representing ~0.14% of shares outstanding. While the dollar amount is modest relative to the $7.2B market cap, the coordinated filing by a director and major venture backers on the same day is a mildly negative signal.